PE20171179A1 - Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas - Google Patents

Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas

Info

Publication number
PE20171179A1
PE20171179A1 PE2017000944A PE2017000944A PE20171179A1 PE 20171179 A1 PE20171179 A1 PE 20171179A1 PE 2017000944 A PE2017000944 A PE 2017000944A PE 2017000944 A PE2017000944 A PE 2017000944A PE 20171179 A1 PE20171179 A1 PE 20171179A1
Authority
PE
Peru
Prior art keywords
solid state
state forms
fused heteroaromatic
refers
compound
Prior art date
Application number
PE2017000944A
Other languages
English (en)
Inventor
Rongliang Chen
Tomonori Ichibakase
Chunrong Ma
Christopher Matthews
Hajime Motoyoshi
Colin O'bryan
Kentaro Yaji
Naoki Yoshikawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171179(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20171179A1 publication Critical patent/PE20171179A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere al compuesto citrato de 6-((1R,2S)-2-aminociclohexilamino)-7-fluoro-4-(1-metil-1H-pirazol-4-il)-1H-pirrolo[3,4-c]piridina-3(2H)-ona y sus determinadas formas de estado solido, caracterizadas por un patron de difraccion de rayos-X de polvo (XRPD) usando radiacion Cu Kalfa que comprende picos en angulos 2 theta de 9.4, 16.6, 17.4, 18.9 y 19.2 ± 0.2 grados, entre otros. Tambien se refiere a una composicion farmaceutica que lo comprende. Dicho compuesto es un inhibidor de la tirosina quinasa del bazo (SYK) siendo util en el tratamiento del cancer tal como linfoma no Hodgkin indolente (iNHL), linfoma de celulas T perifericas (PTCL), entre otros
PE2017000944A 2014-12-18 2015-12-17 Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas PE20171179A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US201562180222P 2015-06-16 2015-06-16

Publications (1)

Publication Number Publication Date
PE20171179A1 true PE20171179A1 (es) 2017-08-22

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000944A PE20171179A1 (es) 2014-12-18 2015-12-17 Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas

Country Status (29)

Country Link
US (3) US10676473B2 (es)
EP (2) EP3233857B1 (es)
JP (3) JP6778195B2 (es)
KR (1) KR102037502B1 (es)
CN (1) CN107108609B (es)
AU (1) AU2015365580B2 (es)
BR (1) BR112017013149B1 (es)
CA (1) CA2970864C (es)
CL (1) CL2017001561A1 (es)
CO (1) CO2017005910A2 (es)
CR (1) CR20170249A (es)
DK (1) DK3233857T3 (es)
DO (1) DOP2017000130A (es)
EA (1) EA032291B1 (es)
EC (1) ECSP17038100A (es)
ES (1) ES2788454T3 (es)
GE (2) GEAP201914545A (es)
IL (1) IL252941B (es)
MX (1) MX373586B (es)
MY (1) MY199935A (es)
NZ (1) NZ732371A (es)
PE (1) PE20171179A1 (es)
PH (1) PH12017501123A1 (es)
PL (1) PL3233857T3 (es)
SG (1) SG11201701911QA (es)
TN (1) TN2017000080A1 (es)
UA (1) UA120632C2 (es)
WO (1) WO2016097862A2 (es)
ZA (1) ZA201701800B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2788454T3 (es) * 2014-12-18 2020-10-21 Takeda Pharmaceuticals Co Formas en estado sólido de pirrolidinonas heteroaromáticas condensadas
US20190231757A1 (en) * 2016-07-13 2019-08-01 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
US12187710B2 (en) 2018-12-14 2025-01-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt of Syk inhibitor and crystalline form thereof
KR20210125519A (ko) 2019-02-07 2021-10-18 얀센 바이오테크 인코포레이티드 다이하이드로오로테이트 탈수소효소 억제제
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
MX2022004335A (es) 2019-10-10 2022-07-19 Janssen Biotech Inc Biarilos como inhibidores de la dihidroorotato deshidrogenasa.
TWI878414B (zh) 2019-12-19 2025-04-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR102539612B1 (ko) 2021-12-24 2023-06-02 엘에스일렉트릭(주) IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템
EP4626426A1 (en) 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
JP2025540762A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5400388B2 (ja) * 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用
DK2516434T3 (en) 2009-12-23 2015-08-31 Takeda Pharmaceutical FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療
ES2788454T3 (es) * 2014-12-18 2020-10-21 Takeda Pharmaceuticals Co Formas en estado sólido de pirrolidinonas heteroaromáticas condensadas

Also Published As

Publication number Publication date
CA2970864A1 (en) 2016-06-23
KR20170095374A (ko) 2017-08-22
AU2015365580A1 (en) 2017-07-06
JP2020143081A (ja) 2020-09-10
JP6778195B2 (ja) 2020-10-28
JP2022017477A (ja) 2022-01-25
IL252941B (en) 2020-11-30
EA032291B1 (ru) 2019-05-31
AU2015365580B2 (en) 2020-04-02
ECSP17038100A (es) 2017-12-01
GEP20197050B (en) 2019-12-10
CL2017001561A1 (es) 2018-01-12
IL252941A0 (en) 2017-08-31
WO2016097862A3 (en) 2016-08-11
UA120632C2 (uk) 2020-01-10
SG11201701911QA (en) 2017-04-27
JP6974534B2 (ja) 2021-12-01
BR112017013149A2 (pt) 2018-04-10
ES2788454T3 (es) 2020-10-21
US20200339573A1 (en) 2020-10-29
EP3677582A1 (en) 2020-07-08
PH12017501123A1 (en) 2017-11-27
PL3233857T3 (pl) 2020-07-27
US20160176869A1 (en) 2016-06-23
CR20170249A (es) 2017-09-25
US20230348461A1 (en) 2023-11-02
GEAP201914545A (en) 2019-08-12
DK3233857T3 (da) 2020-04-27
EP3233857A2 (en) 2017-10-25
CA2970864C (en) 2020-04-14
EP3677582B1 (en) 2023-01-25
NZ732371A (en) 2023-04-28
KR102037502B1 (ko) 2019-10-28
US11352355B2 (en) 2022-06-07
MY199935A (en) 2023-11-29
BR112017013149B1 (pt) 2022-10-11
DOP2017000130A (es) 2017-07-15
US10676473B2 (en) 2020-06-09
EP3233857B1 (en) 2020-03-11
CN107108609A (zh) 2017-08-29
HK1243406A1 (zh) 2018-07-13
TN2017000080A1 (en) 2018-07-04
ZA201701800B (en) 2020-05-27
WO2016097862A2 (en) 2016-06-23
EA201791369A1 (ru) 2017-10-31
CN107108609B (zh) 2020-02-18
JP2017537969A (ja) 2017-12-21
MX373586B (es) 2020-05-05
CO2017005910A2 (es) 2017-10-20
MX2017007162A (es) 2017-08-28

Similar Documents

Publication Publication Date Title
SI2968294T1 (sl) 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo(1,2-A)pirido (4,3-D)pirimidin-5(3H)-on za uporabo pri zdravljenju raka
MX2021006571A (es) Inhibidores de tirosina-cinasas.
CO2017005910A2 (es) Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
CL2016001216A1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CR20140378A (es) Derivados de pirido[2,3-d] pirimidina sustituidos con 2-amino, 6-fenilo útiles como inhibidores de cinasa raf
MY187276A (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CL2014002301A1 (es) Compuestos derivados de pirimidin piridinas sustituidas, inhibidores de serina/treonina cinasas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento de una enfermedad hiperproliferativa tal como melanoma, cancer, leucemias y una enfermedad inflamatoria como artritis y reumatismo entre otras.
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
PE20141792A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
MX361538B (es) Compuestos quimicos.
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2014002604A1 (es) Compuestos derivados de 3,5-disustituido-3h-imidazo[4,5-b]piridina y 3,5-disustituido-3h-[1,2,3]triazolo[4,5-b]piridina, como moduladores de proteina kinasa c-met; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer, tal como carcinoma y sarcoma musculoesqueletico.
CL2014000641A1 (es) Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.
TN2015000313A1 (en) Chemical compounds
CL2015003068A1 (es) Formulaciones farmacéuticas, procesos, formas sólidas y métodos para el uso relacionado con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona
PE20191323A1 (es) PIRAZOLO[3,4-b]PIRIDINAS E IMIDAZO[1,5-b]PIRIDAZINAS COMO INHIBIDORES DE PDE1
MX2017001218A (es) [1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas.
CL2016003102A1 (es) 1h-1,8-naftiridin-2-onas como compuestos antiproliferativos.
ECSP18000097A (es) Inhibidores de tirosina-cinasas
MX375551B (es) Nuevas imidazo[1,2-a]quinoxalinas y derivados de las mismas para el tratamiento contra cancer.